IMC Shares Immuron Limited
ASX · ASXLast in our picks 2026-09-24 — not in the current list; analysis below is from that screen
Tiny liquid exposure with product and commercialization optionality, but investability is limited.
Future value: $0.05 (+8.70%) · 6-12 months
Signal breakdown
- ▸Insufficient scale and liquidity for strong conviction.
- ▸Above 50-day MA (+13.69%)
- ▸Above 200-day MA — long-term uptrend
Is IMC a buy right now?
Trend: IMC is trading below the 50-day average (-7.50%), RSI 48 — neutral momentum, with a 3-month return of +8.82%.
Valuation & quality: Immuron Limited trades on price-to-book 1.06; fundamentals show net margin -47.7%, return on equity -38.3%, revenue growth 7.2% year on year.
Our screen: BUY (score 2) — Tiny liquid exposure with product and commercialization optionality, but investability is limited.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +33.30% | -25.00% | +33.30% | +0.00% | +0.00% | +0.00% |
Fundamentals
Technical signals
About Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada.
Sector: Healthcare · Industry: Biotechnology · Australia · 7 employees · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.